An Open-label Phase 1 Study to Evaluate the Safety and Efficacy of AB-1015 in Patients With Resistant/Refractory Epithelial Ovarian Cancer

Disease Name: 
Ovarian Cancer
Study Status: 
Date: 
April 25, 2023